Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natriuretic Peptides and Metabolic Risk in Obesity
NCT02642523Phase 1Withdrawn
- Sponsor
- Vanderbilt University Medical Center
- Primary completion
- Feb 2017
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised trial of nesiritide and human insulin in obesity and hyperinsulinemia (3 arms), sponsored by Vanderbilt University Medical Center. Primary endpoints: Change in natriuretic peptide levels at 4 hours and Change in glycerol levels at 1 hour. Status: withdrawn.
02
Drugs
nesiritidehuman insulin
03
Conditions
obesityhyperinsulinemia
Beyond the preview
Go deeper on NCT02642523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02642523.